-

Cross Country Healthcare Sets the Record Straight on VDA OC Indictment Report:

DOJ indictment does not involve Cross Country Healthcare

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (NASDAQ: CCRN), today is refuting media reports which erroneously state that a subsidiary and an executive of Cross Country Healthcare were charged in an ongoing US Department of Justice antitrust probe. The charges against this individual and VDA OC do not involve Cross Country Healthcare or any of its executives, subsidiaries or divisions.

“Recent media reports inaccurately suggest that Cross Country Healthcare is involved in the charges brought last night against VDA OC and its former employee,” said Susan Ball, EVP, CAO and General Counsel. “We are immediately requesting a correction with media that have inaccurately included our company in the reporting on this.”

On March 30, a former employee of VDA OC, and VDA OC were indicted on conspiracy charges in violation of antitrust laws. As the Department of Justice release indicates, these events occurred October 2016 until July 2017 which was prior to the Cross Country Healthcare acquisition.

About Cross Country Healthcare

Cross Country Healthcare, Inc. (CCH) is a leader in providing total talent management including strategic workforce solutions, contingent staffing, permanent placement and other consultative services for healthcare clients. Leveraging nearly 35 years of expertise and insight, CCH solves complex labor-related challenges for clients while providing high-quality outcomes and exceptional patient care. As a multi-year Best of Staffing® Award winner, CCH is committed to excellence in delivery of its services and was the first public company to earn The Joint Commission Gold Seal of Approval® for Health Care Staffing Services Certification with Distinction.

Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

Contacts

Cross Country Healthcare, Inc.
Susan Ball, EVP, CAO and General Counsel
561.602.8666
sball@crosscountry.com

Cross Country Healthcare, Inc.

NASDAQ:CCRN

Release Versions

Contacts

Cross Country Healthcare, Inc.
Susan Ball, EVP, CAO and General Counsel
561.602.8666
sball@crosscountry.com

More News From Cross Country Healthcare, Inc.

Cross Country Healthcare Announces Fourth Quarter and Full Year 2024 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2024. SELECTED FINANCIAL INFORMATION: Dollars are in thousands, except per share amounts Q4 2024 Variance Q4 2024 vs Q4 2023 Variance Q4 2024 vs Q3 2024 Full Year 2024   Variance 2024 vs 2023 Revenue $ 309,940       (25 ) %   (2 ) % $ 1,344,004       (33 ) % Gross profit margin*   20.0   %   (190 ) bps   (40 )...

Cross Country’s Susan E. Ball Recognized on SIA’s Global Power 150 Women in Staffing

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare (NASDAQ: CCRN), a leader in workforce solutions and tech-driven staffing, recruitment, and advisory services, proudly announces that Susan E. Ball, Executive Vice President, Chief Administrative Officer, and General Counsel, has been named to Staffing Industry Analysts’ (SIA) prestigious Global Power 150 Women in Staffing List for 2024. This annual list celebrates 150 women worldwide—including 100 from the Americas—who drive significan...

Cross Country Healthcare Announces Third Quarter 2024 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its third quarter ended September 30, 2024. SELECTED FINANCIAL INFORMATION:       Variance Variance       Q3 2024 vs Q3 2024 vs Dollars are in thousands, except per share amounts Q3 2024 Q3 2023 Q2 2024 Revenue $ 315,119     (29 )%   (7 )% Gross profit margin*   20.4 %   (160 )bps   (40 )bps Net income attributable to common stockholders $ 2,555     (80 )%   116 %...
Back to Newsroom